Sarepta lands a valuable priority review voucher on Exondys 51 OK
The FDA has issued a priority review voucher to Sarepta, which it’s already been hawking to deep-pocket drug developers.
The biotech won the PRV …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
